Circulating tumor cells in urological cancers by Cegan, Martin et al.
folia hiStoChEMiCa
Et CYtoBiologiCa
Vol. 55, No. 3, 2017
pp. 107–113
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2017
10.5603/FHC.a2017.0015
www.fhc.viamedica.pl
review
Correspondence address: V. Bobek, M.D., Ph.D.
University Hospital Kralovske Vinohrady
Department of Laboratory Genetics
Srobarova 50, 100 34 Prague, Czech Republic
tel.: +420 26716 3578
e-mail: vbobek@centrum.cz
Circulating tumor cells in urological cancers
Martin Cegan1, Christopher Kobierzycki2, Katarina Kolostova3, imrich Kiss3,  
vladimir Bobek2–4, robert grill5
1Department of Pathology, Masaryk’s Hospital in Usti nad Labem, Usti nad Labem, Czech Republic
2Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland
3Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Prague,  
Czech Republic
4Department of Surgery University Hospital Motol and 1st Faculty of Medicine Charles University, 
Prague, Czech Republic
5Department of Urology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
abstract
Circulating tumor cells (CTC) represent a very small subpopulation of the cancer cells found in the bloodstream 
of patients in the metastatic phase of neoplastic disease. Due to the timeline of the disease, they are regarded 
as a negative prognostic marker. This study focused on determining CTC percentages; these values vary be-
tween different types of cancer. In addition to their diagnostic use, CTCs may also be used to treat the disease. 
Calculating CTC population size and analyzing their biology in patients in advanced stages of cancer may prove 
valuable in creating a molecular profile for the disease. This would strongly encourage diagnostics and enable 
personalized treatment. We here present an analysis of recent data on CTCs in urological cancers and their 
potential uses. (Folia Histochemica et Cytobiologica 2017, Vol. 55, No. 3, 107–113)
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introduction
Disseminated cancer cells that are shed from the 
primary lesion or from metastatic foci into the pe-
ripheral blood are referred to as circulating tumor 
cells (CTCs). They are mostly found in patients in 
advanced metastatic stages of the disease, though 
very rarely they are also observed in premetastatic 
phases [1, 2]. Nevertheless, their number depends 
mostly on the phase of the disease and the type and 
localization of the malignancy. The analysis of their 
presence and characteristics provides a great amount 
of data that cannot be obtained in any alternate way. 
First of all, CTCs may indicate the existence of mi-
crometastases, despite negative results in diagnostic 
imaging. Moreover, the analysis of CTC biology may 
be used to verify chemoresistance and to evaluate the 
differences in primary and secondary tumor focus re-
sponse. Additionally, the presence of CTCs following 
primary radical treatment suggests the risk of cancer 
reoccurrence [3]. In view of above outlined features, 
the application of various methods of CTC testing 
based on blood filtration may have great clinical im-
pact. There are numerous studies being conducted at 
any given time to discover reproducible and reliable 
diagnostic techniques that would enable cells to be 
obtained for precise analysis and to determine their 
biological character. The most important goal is to 
create a reliable and reproducible tool for personal-
ized medicine. The present manuscript presents the 
state of the art in the use of CTCs as individualized 
biomarkers in urological cancers.
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Biology of circulating tumor cells
On account of the many different processes they un-
dergo, the morphology and biology of CTCs is hetero-
geneous and very complex. Generally, they enter the 
bloodstream and move to a location characteristic of 
the tumor type, where they create a metastatic focus. 
In a dynamically proliferating tumor, formation of 
blood vessels occurs rapidly. CTCs in these areas find 
their way into the bloodstream [4]. However, they are 
detected only very rarely among the billions of other 
blood cells, even in patients with advanced stages of 
disease [5]. The use of CTCs in diagnostics seems to 
be hindered because their presence and number may 
not correlate with the severity of disease. Besides 
their scarcity in circulation, CTCs are often highly 
heterogenic due to metastatic subclone development 
in the expression of extraordinary mutational profiles 
during the progression of cancer [6]. In order to cross 
blood vessels walls, remain invisible to elements of 
the immune and coagulation systems, and disperse 
throughout whole body, CTCs must be capable of 
changing their phenotype [7]. The set of changes that 
needs to take place is called the epithelial–mesenchy-
mal transition (EMT) [8]. When cells undergoing this 
transition gain the opportunity to metastasize, they 
lose the determinants typical of epithelial cells and 
begin to express antigens characteristic of cells of 
mesenchymal origin [9, 10]. First of all, cells under-
going EMT cease or lower the expression of epithelial 
cell adhesion molecule (EpCAM) and of cytokeratins 
(CKs). EpCAM is a transmembrane glycoprotein 
primarily responsible for cell-to-cell adhesion, which 
is also involved in cell signaling, migration, prolifer-
ation, and differentiation. CKs are intracytoplasmic 
proteins, elements of the cytoskeleton which help 
epithelial cells resist mechanical stress. Both particles 
are tissue-specific markers, observed only in cells 
originating from epithelial tissue [11, 12]. Simultane-
ously, the upregulation of mesenchymal markers such 
as vimentin (VIM), as well as markers of the EMT 
process, such as twist-related protein (TWIST), is 
observed. VIM is the major cytoskeletal component 
of mesenchymal cells, forming intermediate filaments. 
It plays a significant role in supporting and anchoring 
the position of organelles in the cytoplasm. TWIST 
works as a transcription factor, and is one of the hall-
marks of EMT. Its activation upregulates N-cadherin 
and downregulates E-cadherin, as well as induces 
angiogenesis, extravasation, and chromosomal insta-
bility [11, 12]. 
The exceptional heterogeneity of CTCs is clearly 
visible in advanced breast cancer [13]. Due to their 
individual cancer-associated marker expression and 
tumor-seeding potential originating from their phe-
notypic characteristics, primary and secondary foci 
may require different handling. Nowadays, the golden 
standard in breast cancer diagnostics involves only 
sampling the primary tumor. In view of the above, 
CTCs may survive endocrine treatment in patients 
diagnosed as estrogen receptor (ER)-positive, be-
cause CTCs often lack ER expression [13, 14]. In male 
tumors, decreased therapy effectiveness as a result 
of CTC presence has also been shown. In prostate 
cancer, CTCs expressing mutated androgen receptor 
(AR) and linking variants, such as AR-V7, present 
antiandrogenic therapy resistance [15, 16].
Detection of circulating tumor cells 
There are two main challenges to the detection of 
CTCs: their rare occurrence in the blood and diffi-
culties in identifying the appropriate cells for further 
isolation [15, 17]. To comprehend this extremely small 
quantity of cells, we need to realize that a 7.5 mL 
blood sample obtained from a patient with a solid 
malignancy contains approximately 1 CTC alongside 
10 million white blood cells. Direct identification is 
based on a combination of negative and positive im-
munological selection of nonepithelial and epithelial 
cells, respectively. On the other hand, indirect detec-
tion mainly involves the analysis of epithelial-specific 
mRNA transcripts by RT-PCR. Most existing methods 
of CTC capture are based on immunoaffinity to Ep-
CAM, which is generally overexpressed in various can-
cers; it is present in 97% cases of colon cancers, though 
only 41.7% of patients with primary malignant breast 
cancer show increased EpCAM expression [18, 19]. 
On the other hand, EpCAM expression appears to be 
downregulated in CTCs, and the relationship between 
EpCAM expression at the primary breast cancer focus 
and in CTCs is unclear [20]. The occurrence of the 
EMT process with all its features may be a reason 
for the high rate of false positives in CTC detection 
based on EpCAM enrichment techniques. The ideal 
method of CTC detection would be isolation based on 
cell size, meaning that tumor cells would be captured 
in accordance with their size from different segments 
of the peripheral blood. An additional benefit would 
be the possibility of in vitro cultivation, which would 
enable differentiation between malignant and benign 
epithelial cells [21–25].
Use of circulating tumor cells
The term biomarker encompasses a broad group of 
determinants, such as clinical, laboratory, genetic, 
molecular and imaging-based approaches [26]. They 
are primarily employed in diagnostics to differentiate 
healthy specimens from pathological specimens, most-
ly in doubtful cases. They give additional data about 
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the advancement of the disease and about survival 
rates. Moreover, treatment efficacy and recurrence 
risk may be monitored through marker analysis. The 
specificity of CTCs as biomarkers is that they represent 
the individual tumor cells of individual patients and 
reflect the heterogeneity of possible metastatic sites.
Prostate cancer
The selection of the most suitable therapy for prostate 
cancer is currently based on the Gleason score (his-
topathological analysis) and the serum level of pros-
tate-specific antigen (PSA). Unfortunately, the low 
specificity of PSA is well known. It can be similarly in-
creased in benign hyperplasia, indolent lesions of epi-
thelial origin (IDLE), and even aggressive lesions [27]. 
In addition, it is inappropriate for therapy monitor-
ing, due to its low accuracy in treatment response 
verification.
Nowadays, CTCs are generally accepted as prog-
nostic biomarkers in prostate cancer. The prognostic 
value of the baseline CTC level has been evaluated in 
numerous studies in which patients were treated with 
chemotherapy and androgen receptor (AR) signaling 
inhibitors [28–33]. Various studies have shown an 
association between baseline CTCs levels and clinical 
outcomes in metastatic patients [28, 29, 32, 34]. De-
creased levels of CTCs in the bloodstream of patients 
after therapy correlated with longer overall survival 
(OS), which was subsequently observed as decreased 
PSA level and radiographic response [28, 35]. Most 
importantly, alterations in CTCs levels predate PSA 
changes, suggesting the usefulness and high accuracy 
of method for monitoring cancer treatment [29].
Numerous prospective clinical trials have assessed 
presence of CTCs as an intermediate end point. 
SWOG S0421 was a phase III double-blind, rand-
omized placebo-controlled trial evaluating patients 
with metastatic castration-resistant prostate cancer 
(mCRPC) starting first-line docetaxel chemotherapy 
with or without atrasentan [30]. Atrasentan is an 
endothelin receptor antagonist that blocks endothe-
lin-induced cell proliferation. CTCs were found to 
provide additional discriminatory value (independent 
prognostic marker) over the PSA level and other fac-
tors. Atrasentan had no influence on OS [30]. 
COU-AA-301 was a phase III double-blind ran-
domized placebo-controlled trial evaluating whether 
CellSearch-based CTCs enumeration could be used 
as a surrogate efficacy-response biomarker of OS [32]. 
Patients with mCRPC who had previously been 
treated with docetaxel received abiraterone with 
prednisone versus prednisone alone. Abiraterone 
is a steroidal CYP17A1 inhibitor and, by extension, 
an androgen synthesis inhibitor. Baseline favorable 
versus unfavorable CTCs counts measured on the 
CellSearch platform were associated with better 
OS (26 vs. 13 months, HR = 2.74, p = 0.001). Any 
increase in CTCs count after one cycle of docetaxel 
treatment was significantly associated with worse OS, 
whereas a decrease in CTCs counts pointed to an 
insignificant trend towards improved OS [36]. These 
data suggest that the detection of rising CTCs counts 
during docetaxel chemotherapy may be used for clin-
ical verification of the therapy. Moreover, 1195 men 
with mCRPC who had previously received docetaxel 
benefited from abiraterone acetate treatment [37]. 
Thus, CTCs enumeration could be used as a surrogate 
efficacy-response biomarker of OS [32]. 
A study analyzing levels of PSA, LDH (lactate 
dehydrogenase), and CTCs in patients treated with 
abiraterone showed interesting relationships. Abi-
raterone treatment (HR = 0.70, p < 0.0001), baseline 
LDH concentration (HR = 2.98, p < 0.0001), and 
CTC count (HR = 1.19, p < 0.0001) were prognostic 
for survival, while PSA level was not (HR = 1.04, 
p = 0.1797) [38]. A “CTCs biomarker panel”, com-
posed of CTCS count and LDH serum activity, cate-
gorized subjects as low risk (CTCs count ≤ 4 cells per 
7.5 mL of blood, any LDH), intermediate risk (CTCs 
count ≥ 5, LDH ≤ 250 U/L), and high risk (CTCs 
count ≥ 5, LDH > 250 U/L). The CTCs biomarker 
panel discriminated survival time and satisfied the 
four Prentice criteria for surrogacy [38], unlike the 
CTCs count or LDH as individual variables [32]. 
These prospective phase III data from SWOG S0421 
and COU-AA-301 trials are encouraging and require 
validation by ongoing, independent phase III clinical 
trials. 
The majority of mCRPC patients are diagnosed in 
the bone involvement phase. In this case, the Response 
Evaluation Criteria in Solid Tumors cannot be applied 
for interpretation. New treatment response bio-
markers are thus acutely needed for CRPC patients. 
The Prostate Cancer Working Group 2 criteria rely 
on bone scintigraphy and changes in the PSA levels to 
evaluate response to treatment in these patients [39]. 
However, progression according to bone scintigraphy 
is not evaluable before 16 weeks of treatment, and 
most studies evaluating decrease in PSA levels as 
a surrogate of survival have yielded negative results; 
treatment based solely according to PSA values is not 
recommended [39–42]. 
Verification of radiological progression free 
survival (PFS) cannot currently be acquired before 
at least 12–16 weeks of treatment, and is difficult in 
the evaluation of widespread bone involvement [43]. 
An additional post hoc analysis of data for patients 
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in prospective IMMC-38 (chemotherapy) and 
COU-AA-301 (abiraterone) trials with baseline 
CTCs ≥ 5 cells per 7.5 mL was performed in 2016, 
and evaluated the value of a 30% CTCs decline from 
baseline at 4, 8, and 12 weeks of treatment [33]. The 
OS in patients with mCRCP after abiraterone and 
chemotherapy is associated with a 30% decrease in 
CTC level from the original number of ≥ 5 cells per 
7.5 mL. Further prospective studies are needed to 
evaluate this promising surrogate.
urothelial cancer
There is still lack of diagnostic biomarkers with satis-
factory prognostic and predictive value in urothelial 
cancers. Besides, all the tests analyze urine samples, 
and so cannot be used in extravesical tumor diagnos-
tics. The greatest advantages of serum markers are 
their minimal invasiveness and their possible use in 
the monitoring of treatment effectiveness, mostly in 
comparison to surgical biopsies of metastatic sites. 
There are studies outlining the use of CTCs in super-
ficial and invasive urothelial cancers [44, 45]. 
It has been shown that CTC-positive patients who 
have undergone radical cystectomy had a higher risk 
of recurrence and reduced OS [46, 47]. Moreover, 
CTC positivity was found to be an isolated risk factor 
of reduced OS [47, 48]. Alarmingly, the presence of 
a single CTC in a patient’s bloodstream was correlat-
ed with reduced survival in patients with urothelial 
carcinoma of the bladder [46]. Apart from research 
that examined the quantity of CTCs, there are also 
studies on their quality. Osman et al. compared CTCs 
with and without uroplakin/EGFR mRNAs in patients 
who had undergone radical cystectomy [49]. The first 
group (uroplakin/EGFR+) had a higher risk of recur-
rence. Gudemann et al. analyzed the presence of CKs 
in CTCs, revealing cancer development potential in 
CTCs that expressed CK20, which was also associated 
with clinical stage/disease burden [50].
renal cancer
A small number of studies have been published on 
the detection of CTCs in metastatic renal cell carci-
noma (mRCC). An association was found between 
the presence of CTCs, lymph node involvement, and 
the presence of metastases at the time of diagnosis in 
mRCC [51]. Studies have also shown that the presence 
and quantity of mesenchymal and stem-cell-like CTCs 
is associated with poor treatment response. The pres-
ence of stem-cell-like CD133+ cells or mesenchymal 
N-cadherin+/CK- cells correlates with shortened PFS. 
Moreover, in cases with detectable CD133+ cells, 
N-cadherin+/CK- cells were often found [52]. 
Molecular characterization  
of circulating tumor cells 
The ability to detect CTCs in patients with various 
diseases has given clinicians the opportunity to im-
prove the diagnostic screening and monitoring of the 
therapy employed. Moreover, to determine the full 
informative potential of CTCs, the laboratory tests 
include DNA, RNA, and protein analysis. Pooled 
CTCs analyses offer the potential to assess the 
dominant circulatory clone at a given point in time 
in a specific patient, and allow the tracking of clonal 
selections during systemic therapies. The evolution of 
the molecular development of circulating cells from 
the primary or metastatic sites could be reproduced 
by personalized CTCs profiling, which could lead to 
the ability to detect uncommon resistant clones. For 
example, AR has recently been a deeply studied area 
in prostate cancer, also in view of CTCs. The level 
of expression of complete AR or its splice variants 
correlates directly with clinical outcome and response 
[16, 53]. It has been shown that patients with the 
expression of AR-V7 (the most frequent variant) 
present abiraterone and enzalutamide resistance 
[16]. The clinical importance of circulating AR-V7 as 
a marker of resistance to inhibition of the androgen/ 
/androgen receptor axis has been supported by whole-
blood PCR assays detecting AR-V7 mRNA without 
prior CTC enrichment [54]. Similarly, Anonarakis 
et al. studied patients with overexpressed AR-V7 who 
were resistant to abiraterone treatment, showing no 
influence on PSA level [16]. The detection of AR-V7 
in mCRPC patients may lead to a reduction in ineffec-
tive abiraterone and enzalutamide treatment, which 
would be healthful for patients and cost-beneficial to 
healthcare providers. AR-V7 testing in clinical phase 
is presently ongoing [54]. However, Bernemann et al. 
have indicated that patients with mCRPC and positive 
AR-V7 CTCs should not be excluded from either next 
generation androgen deprivation therapy or abirater-
one or enzalutamide treatment as long as no appro-
priate alternative therapy has been introduced [55]. 
In prostate cancer patients, examination of CTCs 
revealed mutations in the erythroblastosis virus 26 
oncogene homolog gene (ERG). This leads to the 
synthesis of an ERG oncogene with the AR-driven 
TMPRSS2 promoter and has been identified in more 
than 50% of hormone-sensitive prostate cancers with 
preserved further tumor progression [56, 57]. Recog-
nizing this as a potential predictive factor, patients 
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with specific ERG mutations can be expected to be 
more sensitive to abiraterone therapy [58].
The routinely preformed analysis of proliferation 
marker Ki67 seems to also have diagnostic potential in 
prostate cancer. Its expression in CTCs positively cor-
relates with expression levels and nuclear localization 
of ARs, and likewise with the stage of advancement 
of prostate cancer [59]. Patients with positive Ki-67 
CTCs during therapy are theoretically resistant to 
treatment, and therefore Ki-67 has the potential to 
be used as marker of therapy effectiveness. 
Conclusion
In summary, it is essential to undertake larger and 
more detailed analyses of the molecular character-
istics of CTCs in urological tumors. Understanding 
the biology of CTCs will provide a new quality of di-
agnostic and therapeutic strategies, which will enable 
effective personalized treatment and prevention of 
metastatic process.
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